Actively Recruiting

Phase 3
Age: 2Years - 50Years
All Genders
NCT06914609

REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome

Led by Ionis Pharmaceuticals, Inc. · Updated on 2026-05-14

158

Participants Needed

38

Research Sites

250 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.

CONDITIONS

Official Title

REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome

Who Can Participate

Age: 2Years - 50Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Caregiver or legal representative has given written informed consent and agrees to comply with study requirements
  • Medically stable and able to undergo sedation and/or general anesthesia without intubation
  • Male or female aged between 2 and 50 years at screening
  • Clinical diagnosis of Angelman syndrome with molecular confirmation of UBE3A deletion or mutation
  • Receiving stable doses of medications or nutritional support for Angelman syndrome for at least 8 weeks prior to baseline
  • Caregiver agrees not to post participant's personal medical data or study information on social media until study completion
Not Eligible

You will not qualify if you...

  • Clinically significant medical history or conditions contraindicating antisense oligonucleotide treatment or that could affect study results
  • Known brain or spinal diseases affecting lumbar puncture safety or cerebrospinal fluid circulation
  • Any condition that could interfere with participation or study completion as judged by the Investigator
  • Laboratory abnormalities or other clinically significant issues at screening or baseline making participation unsuitable
  • Previous treatment with gene therapies or oligonucleotides like siRNA or ASOs (except approved nucleic acid vaccines)
  • Angelman syndrome due to paternal uniparental disomy, imprinting center defect, or mosaic findings
  • Other criteria as determined by study investigators

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 38 locations

1

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048

Actively Recruiting

2

Rady Children's Hospital

San Diego, California, United States, 92123

Actively Recruiting

3

Colorado Children's Hospital Research Institute

Aurora, Colorado, United States, 80045

Actively Recruiting

4

Children's National Hospital

Washington D.C., District of Columbia, United States, 20011

Actively Recruiting

5

Nicklaus Children's Hospital

Miami, Florida, United States, 33155

Actively Recruiting

6

Children's Healthcare of Atlanta

Atlanta, Georgia, United States, 30329

Actively Recruiting

7

Rush University Medical Center

Chicago, Illinois, United States, 60612

Actively Recruiting

8

Boston Children's Hospital

Boston, Massachusetts, United States, 02115

Actively Recruiting

9

Children's Mercy

Kansas City, Missouri, United States, 64108

Actively Recruiting

10

Ichan School of Medicine at Mount Sinai

New York, New York, United States, 10029

Actively Recruiting

11

University of North Carolina at Chapel Hill School of Medicine

Carrboro, North Carolina, United States, 27510

Actively Recruiting

12

Nationwide Children's Hospital

Columbus, Ohio, United States, 43205

Actively Recruiting

13

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

14

Vanderbilt Clinical Research Center

Nashville, Tennessee, United States, 37232

Actively Recruiting

15

Texas Children's Hospital

Houston, Texas, United States, 77030

Actively Recruiting

16

Queensland Children's Hospital

South Brisbane, Queensland, Australia, 4101

Actively Recruiting

17

Perth Children's Hospital

Nedlands, Australia, 6009

Actively Recruiting

18

Sydney Children's Hospital

Randwick, Australia, 2031

Actively Recruiting

19

London Health Science Centre - Children's Hospital

London, Ontario, Canada, N6A 5W9

Actively Recruiting

20

McGill University Health Centre

Montreal, Quebec, Canada, H4A 3J1

Actively Recruiting

21

University of Alberta Hospital

Edmonton, Canada, T6G 2B7

Actively Recruiting

22

British Columbia Children's Hospital

Vancouver, Canada, V6H 3V4

Actively Recruiting

23

Klinikum der Ludwig-Maximilians-Universitaet Muenchen

München, Germany, 81377

Actively Recruiting

24

Sheba Medical Center

Ramat Gan, Israel, 5265601

Actively Recruiting

25

Associazione La Nostra Famiglia - IRCCS Eugenio Medea

Conegliano, Italy, 31015

Not Yet Recruiting

26

Fondazione IRCCS Istituto Neurologico Carlo Besta

Milan, Italy, 20133

Not Yet Recruiting

27

Azienda Ospedaliero Universitaria Pisana

Pisa, Italy, 56126

Actively Recruiting

28

Ospedale Pediatrico Bambino Gesù

Roma, Italy, 00165

Not Yet Recruiting

29

Osaka Women's and Children's Hospital

Izumi, Osaka, Japan, 594-1101

Actively Recruiting

30

National Center of Neurology and Psychiatry

Kodaira, Tokyo, Japan, 187-8551

Actively Recruiting

31

Uniwersyteckie Centrum Kliniczne

Gdansk, Poland, 80-952

Actively Recruiting

32

KK Women's and Children's Hospital

Singapore, Singapore, 229899

Actively Recruiting

33

Seoul National University Hospital

Seoul, South Korea, 03080

Actively Recruiting

34

Samsung Medical Center

Seoul, South Korea, 06351

Actively Recruiting

35

Hospital Sant Joan de Deu

Barcelona, Spain, 08950

Actively Recruiting

36

Corporacio Sanitaria Parc Tauli - Hospital de Sabadell

Sabadell, Spain, 08208

Actively Recruiting

37

Great Ormond Street Hospital for Children - NHS Foundation Trust

London, United Kingdom, WC1N 3JH

Actively Recruiting

38

John Radcliffe Hospital

Oxford, United Kingdom, OX3 9DU

Actively Recruiting

Loading map...

Research Team

I

Ionis Pharmaceuticals, Inc.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome | DecenTrialz